Stocktoria
Neumora Therapeutics, Inc. NMRA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-09-15
Neumora Therapeutics, Inc. statistics & valuation
Market cap$303.9M
P / B2.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Return on assets | -124.0% | -76.9% | -47.5% | -30.7% |
| Return on equity | -228.1% | -84.9% | -50.3% | 29.3% |
| Debt / equity | 0.52× | 0.00× | — | — |
| Current ratio | 5.87 | 10.51 | 19.05 | 16.37 |
Source: SEC EDGAR filings · CIK 0001885522 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.